AR018472A1 - COMPOSITE, COMPOSITION AND METHOD FOR THE TREATMENT OF HAIR LOSS - Google Patents

COMPOSITE, COMPOSITION AND METHOD FOR THE TREATMENT OF HAIR LOSS

Info

Publication number
AR018472A1
AR018472A1 ARP000100917A ARP000100917A AR018472A1 AR 018472 A1 AR018472 A1 AR 018472A1 AR P000100917 A ARP000100917 A AR P000100917A AR P000100917 A ARP000100917 A AR P000100917A AR 018472 A1 AR018472 A1 AR 018472A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroalkynyl
heteroalkenyl
heteroalkyl
alkynyl
Prior art date
Application number
ARP000100917A
Other languages
Spanish (es)
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of AR018472A1 publication Critical patent/AR018472A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
    • C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
    • C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Abstract

Compuestos y composiciones particularmente utiles para tratar la pérdida del cabello en mamíferos, incluyendo detener y/o revertir y estimularel crecimiento de éste. Los compuestos tienen una estructura bifenílica (I) y, preferiblemente, no afectan al corazon, en donde: R1, R2, R5, R7 y R10 son cadauno de manera independiente, seleccionados entre hidrogeno, halogeno, alquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo y heteroalquinilo;R4 es seleccionado entre el grupo consistente en halogeno, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, arilalquilo, heteroalquilo,heteroalquenilo, heteroalquinilo, heterocicloalquilo, heterocicloalquenilo, heteroarilo, heteroarilalquilo, y heteroarilalquenilo; con lacondicionde que cuando R2 es hidrogeno, Y es -CH2CHK1, X es seleccionado entre -NZ- y -NH- y R12 es alquilo C1-4, en donde K1 es seleccionada entrehidrogeno y alquilo C1-4 y Z es alquilo C1-4, entonces R4 no sea arilalquilo; R8 y R9 son cada uno de manera independiente, seleccionados entre hidrogeno,halogeno, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, arilalquilo, heteroalquilo, heteroalquenilo, heteroalquinilo, heterocicloalquilo,heterocicloalquenilo, heteroarilo, heteroarilalquilo y heteroarilalquenilo; con la condicion que por lo menos uno, entre R8 y R9, no sea hidrogeno; R3 esseleccionado entre hidrogeno, alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, arilo, arilalquilo, heteroalquilo, heteroalquenilo, heteroalquinilo,heterocicloalquilo, heterocicloalquenilo, heteroarilo, heteroarilalquilo y heteroarilalquenilo; Y es seleccionado entre un enlace, alquilo, alquenilo,alquinilo, heteroalquilo, heteroalquenilo y heteroalquinilo; X es seleccionado entre -NZ-, -NH- y -O-; R11 es seleccionado entre un enlace y -C(O)-; con lacondicion que cuando Y es un enlace y X es -O-, luego R11 será -C(O)-; y cuando Y es alquilo y X es -O- entonces R11 no será -C(O)-; R12 es seleccionado entrealquilo, alquenilo, alquinilo, heteroalquilo, heteroalquenilo, heteroalquinilo, cicloalquilo, cicloalquenilo, heterocicloalquilo, heterocicloalquenilo, arilo,Compounds and compositions particularly useful for treating hair loss in mammals, including stopping and / or reversing and stimulating hair growth. The compounds have a biphenyl structure (I) and, preferably, do not affect the heart, where: R1, R2, R5, R7 and R10 are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl and heteroalkynyl; R4 is selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, heteroarylalkyl; with the proviso that when R2 is hydrogen, Y is -CH2CHK1, X is selected from -NZ- and -NH- and R12 is C1-4 alkyl, where K1 is selected from hydrogen and C1-4 alkyl and Z is C1-4 alkyl , then R4 is not arylalkyl; R8 and R9 are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, heteroarylalkyl and heteroaryl; with the condition that at least one, between R8 and R9, is not hydrogen; R3 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, arylalkyl, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, heteroarylalkyl and heteroarylalkyl; Y is selected from a bond, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl and heteroalkynyl; X is selected from -NZ-, -NH- and -O-; R11 is selected from a link and -C (O) -; with the condition that when Y is a bond and X is -O-, then R11 will be -C (O) -; and when Y is alkyl and X is -O- then R11 will not be -C (O) -; R12 is selected from alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl,

ARP000100917A 1999-06-01 2000-03-01 COMPOSITE, COMPOSITION AND METHOD FOR THE TREATMENT OF HAIR LOSS AR018472A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13695899P 1999-06-01 1999-06-01

Publications (1)

Publication Number Publication Date
AR018472A1 true AR018472A1 (en) 2001-11-14

Family

ID=22475200

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100917A AR018472A1 (en) 1999-06-01 2000-03-01 COMPOSITE, COMPOSITION AND METHOD FOR THE TREATMENT OF HAIR LOSS

Country Status (7)

Country Link
EP (1) EP1183074A1 (en)
JP (1) JP2003500459A (en)
AR (1) AR018472A1 (en)
AU (1) AU3507600A (en)
CA (1) CA2375822A1 (en)
MX (1) MXPA01012491A (en)
WO (1) WO2000072920A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664291B2 (en) 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
ES2267945T3 (en) * 2001-05-31 2007-03-16 Pfizer Products Inc. MEDICAL USE OF TIROMIMETIC COMPOUNDS TO TREAT LOSS OF HAIR AND COMPOSITIONS.
US7169564B1 (en) 2001-06-26 2007-01-30 Anaderm Research Corporation FKBP51/52 and CyP40-mediated mammalian hair growth
DE10131462A1 (en) * 2001-06-29 2003-01-09 Bayer Ag Phenol derivatives
DE60208132T2 (en) 2001-09-26 2006-07-20 Pfizer Products Inc., Groton Indolocarboxylic acid as a thyroid receptor ligand
US8741966B2 (en) 2007-11-09 2014-06-03 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
EA021177B1 (en) 2009-05-08 2015-04-30 Пронова Биофарма Норге Ас Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
NZ610705A (en) 2010-11-05 2014-10-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
EP2695611B1 (en) 2012-08-06 2014-10-01 Dr. August Wolff GmbH & Co. KG Arzneimittel Eprotirome for use in the prevention and/or treatment of hair disorders and compositions thereof
EP2961384B1 (en) 2013-02-28 2019-08-28 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
US20180104201A1 (en) 2015-04-28 2018-04-19 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic steatohepatitis
SG11202005007VA (en) 2017-12-06 2020-06-29 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69314718T2 (en) * 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamic acid derivatives as hypocholesteremic agents
AU4990496A (en) * 1995-02-23 1996-09-11 Life Medical Sciences, Inc. Compositions and methods for enhancing the growth of hair and restoring hair color

Also Published As

Publication number Publication date
WO2000072920A1 (en) 2000-12-07
CA2375822A1 (en) 2000-12-07
AU3507600A (en) 2000-12-18
JP2003500459A (en) 2003-01-07
MXPA01012491A (en) 2002-07-02
EP1183074A1 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
AR018472A1 (en) COMPOSITE, COMPOSITION AND METHOD FOR THE TREATMENT OF HAIR LOSS
PA8546301A1 (en) QUIRAL SALT RESOLUTION
DE50009643D1 (en) TENSID COMPOSITION CONTAINING GEMINITENSIDE AND CO-AMPHIPHILES, THEIR PREPARATION AND THEIR USE
AR008384A1 (en) TOPIC COMPOSITION FOR THE TREATMENT OF SKIN CONDITIONS, USE OF THE COMPOUND FOR THE PREPARATION OF A NON-THERAPEUTIC MEDICINAL PRODUCT AND METHOD FOR SKIN POLISHING AND HAIR SOFTENING.
AR006867A1 (en) TOPIC SKIN COMPOSITION INCLUDING AN OXA-DIÁCIDO COMPOUND, ITS USE TO PREPARE A MEDICATION TO TREAT SKIN CONDITIONS AND NON-THERAPEUTIC COSMETIC METHODS FOR SKIN POLISHING AND TO SOFTEN THE APPLIED HAIR.
AR042461A1 (en) ANALOGS 2-SUBSTITUTED FOR QUINAZOLIN-4-IL - AMINA. PHARMACEUTICAL COMPOSITIONS
DK0736039T3 (en) Compounds with growth hormone-releasing properties
PE20001303A1 (en) DERIVATIVES OF 4-AROYLPIPERIDINE AS ANTAGONISTS OF THE CCR-3 RECEPTOR
GT199900067A (en) NEW 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURTIC DEDERMATOSIS.
PE20000422A1 (en) AMIDINE COMPOUNDS
PE20011047A1 (en) AMIDA COMPOUND AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINASES
PE129099A1 (en) DERIVATIVES OF THENOPyrimidine AND THENOPyridine USEFUL AS ANTI-CANCER AGENTS
UY23835A1 (en) PROCEDURE FOR THE PREPARATION OF ACIL COMPOUND
MX9403380A (en) HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS.
CR6592A (en) COMPOUNDS FOR THE TREATMENT OF THE ISCHEMIA
ES8600737A1 (en) Sulfonium compounds, processes for preparing the compounds and pharmacological composiitons containing the same
ATE364043T1 (en) PYRAZOLO-PYRIDINE FOR THE TREATMENT OF HERPES INFECTIONS
ATE326466T1 (en) IMIDAZOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HERPES VIRUS INFECTION
AR031975A1 (en) ANALOG COMPOUNDS OF (1R, CIS) -4- (6-AMINO-9H-PURIN-9-IL) -2-CYCLOPENTENE-1-METHANOL, PROCESS FOR PREPARATION, USE IN THE TREATMENT OF VIRAL INFECTIONS, AND PACKING THAT CONTAINS THEM
ZA839693B (en) Substituted 4-aminomethylene-chromans and-chromens,processes for their preparation and their use in medicaments
AR018700A1 (en) COMPOSITE, COMPOSITION AND METHOD FOR THE TREATMENT OF HAIR LOSS
DE69333413D1 (en) 5-HT2 ANTAGONISTS IN TREATING VENOUS STATES
ES2043891T3 (en) PROCEDURE FOR PREPARING NEW ANTIARRHYTHMIC AGENTS II.
AR018164A1 (en) PROCESS FOR THE PREPARATION OF CIS-CICLOHEXILIDENAMINAS
SE9702563D0 (en) Compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal